A B S T R A C T The reduced capacity of patients with multiple myeloma to respond to antigen challenge is well recognized. Response to antigen involves antigen recognition, cell proliferation, and synthesis and secretion of antibody. This study examines this sequence of events in peripheral blood lymphocytes from untreated and treated patients with myeloma, from individuals with benign monoclonal gammopathy, and from normal healthy donors. Antigenbinding capacity was assessed by testing the ability of lymphocytes to bind radio-labeled pneumococcal polysaccharide, tetanus toxoid, or diptheria toxin. The in vitro proliferative response to these antigens as well as to pokeweed mitogen and streptokinasestreptodomase was evaluated. The secretion of immunoglobulin in response to pneumococcal polysaccharide, tetanus toxoid, and pokeweed mitogen by [2] [3] [4] x 106 lymphocytes in 7-day cultures was determined. The effects of coculture of myeloma peripheral blood lymphocytes and normal peripheral blood lymphocytes on immunoglobulin production and mixed leukocyte reactions were explored. All myeloma patients had normal numbers (3-8/5 ,000 cells) of antigen-binding cells. However, most showed a diminished antigen-induced blast transformation as measured by uptake of [125I ]5-iodo-2'-deoxyuridine in culture. Immunoglobulin production in response to specific antigen in myeloma lymphocytes was 30-80% less than in normal lymphocytes. Immunoglobulin synthesis and mixed leuikocyte responses by normal peripheral blood lymphocytes could be suppressed by myeloma lymphocytes. Mtultiple suppressor populations were present. Thus, the immune defect in myeloma is beyond the antigen recognition step and involves both the proliferation of antigen-sensitive cells and immunoglobulin production. Further suppressive effects are imposed on normal cells, implying defects in immunoregulation in this disease.
INTRODUCTION
Multiple myeloma is a disease characterized by malignant proliferation of plasma cells resulting in bone marrow replacement, osteolytic bone lesions, and paraprotein production. Despite the increased paraprotein production seen in many patients with multiple myeloma, there is impairment of polyclonal immtunoglobulin synthesis as demonstrated both functionally by decreased capacity to form specific antibody, and clinically by increased susceptibility to certain bacterial infections (1) . Lack of antigen-binding cells (ABC),' faulty expansion of the antigen-triggered immunocyte pool, increased catabolism of immunoglobulin, presence of "chalones" affecting maturation of bone marrow-derived (B) lymphocyte immunoglobulin synthesizing capacity, or presence of suppressor cells affecting B-cell maturation could all contribute to the observed immunoglobulin synthesis impairment (2) (3) (4) (5) . Data to be presented suggest that in patients with multiple myeloma, there are sufficient numbers of ABC that circulating lymphocytes have reduced capacity to undergo transition to immunoglobulinsecreting cells when exposed to pokeweed mitogen and certain antigens, that a suppressor cell population contributes to decreased immunoglobulin production, and that suppressor cell populations for other cell I Abbreviations used in this paper: ABC, antigenbinding cells; BMG, benign monoclonal gammopathy; BSA, bovine serum albumin; EAC-RFL, lymphocytes forming rosettes with sheep erythrocytes coated with IgM antisheep erythrocyte antibody and C3 from human serum; EA-RFC, cells forming rosettes with human type 0 Rhpositive erythrocytes coated with human anti-D immuno-functions may play a role in this disease. Such observations are significant in relation to approaches to therapy in this disease.
METHODS
Patient selection. 30 different healthy volunteer donors between 22 and 69 yr of age who were receiving no medication were used as controls. A total of 32 different patients with multiple myeloma between 55 and 89 yr of age (9 of these patients were untreated at the time of study) and 15 different patients with benign monoclonal gammopathy were included in these studies. The diagnosis of multiple myeloma was based on at least two of the following findings: (a) discovery of plasma cells constituting more than 20% of the total nucleated cellularity of aspirated bone marrow without other known cause, (b) presence of a monoclonal serum or urine gamma globulin peak on electrophoresis in combination with a reduction of other serum immunoglobulins, and (c) presence of bony lesions in the skull, vertebral column, or pelvic bones. Patients with multiple myeloma were treated with intermittent dosages of alkylating agents and corticosteroids, and were sampled 4-6 wk after their last drug cycle. All multiple myeloma patients tested had IgA Populations enriched for thymus-derived (T) cells were obtained using three different methods. (a) Surface immunoglobulin-positive lymphocytes were removed from FicollHypaque lymphocyte preparations by passage through nylon fiber columns using methods described by Greaves and Brown (9) . Briefly, 300 mg of sterile washed nylon fibers (Nylon fiber LP 1 Leuko-pack, Fenwal Inc., Ashland, Mass.) were packed in 5-ml sterile plastic syringes. Columns were equilibrated at 37°C with RPMI 1640 supplemented with 2 mM glutamine, 15% decomplemented-pooled gammaglobulin-free AB serum, 100 U/ml penicillin, and 100 ,ug/ml streptomycin. Viable lymphocytes (5 x 107 in 1 ml) were added to the equilibrated columns. Lymphocytes were eluted with 10 ml of supplemented RPMI 1640 at a rate of 2 ml/min. Approximately 50%o of the cells applied to the columns were recovered. Viability was 90% or greater. Eluted cell subpopulations contained less then 2% immunoglobulin-positive lymphocytes as judged by standard immunofluorescence methods (10) and less than 1% monocytic cells as judged by nonspecific esterase stains and latex particle ingestion. (b) Cells forming rosettes with human type 0 Rh-positive erythrocytes coated with human anti-D immunoglobulin were removed from Ficoll-Hypaque-purified monocytedepleted lymphocyte preparations by methods previously described (11) . Ficoll-Hypaque-purified monocyte-depleted peripheral blood leukocytes (PBL) (20 x (16) . Briefly, 2 x 106 Ficoll-Hypaquie-pturified lvmphocytes/ml in 2-mI cuilthires were incubated at 37°C in a 5% C02-humiiidified incubator in RPMI 1640 stupplemented with 2 mM glitamine, 20% decomplemented fetal calf seruim, 100 U/ml penicillin, and 100 ()g/,ml streptomycin in 13 x 100-mmil plastic cuiltuire tubes (Falcon Plastics) in the presence or absence of op)timal amounts of PWM, TT, or PP. After 7 days in cultuire, tubes were centrifuiged at 2,500 rpm for 10 min. The amount of IgG or IgM synthesized and secreted into the cuiltture supernate was determined by a double-antibody radioimmunnoassay. Specificity of antisera used in these experiments was determined as described in the antisera section above. 1 mg of IgG or IgM in 1 ml of 0.05 M phosphate buffer, pH 7.0, was labeled with 2-3 mCi 1251 using a chloramiine-T method. The dilution of anti-IgG or anti-IgM which would bind 60% of a suitable amount of labeled IgG or IgM was determined. Antigen-antibody dilution curves were constnicted over an antigen range of 1.0-0.1 gg of labeled antigen and 1:10-1:500 dilution of antisera. The amouint of goat anti-rabbit gamma globulin added to precipitate the rabbit immunoglobulin was twice the equiivalence amount.
In the actual assav, a dilution of cultuire supernate or standard (0.05 ml) was added to 0.05 ml of anti-IgG or anti-IgM for 3 h at room temperature. Then 0.05 ml of goat anti-rabbit immuinoglobuilin was added to the 10 x 75-mmnl siliconized glass tubes which were incubated for 15 h at 4°C. After overnight incubation, 1 
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T. Paglieroni and M. R. MacKenzie or allogeneic. nrmal patients (4 x 106 cells in 2-ml cultures in RPMI 1610 supplemented as above) were incubated with equal concentrations of lymphocytes from normal control patients in the presence of 20 ,ul/culture PWM(the total culture volume was 4 ml). Preliminary experiments showed that in most cases, 20 .1/culture PWM produced maximal stimulation of immunoglobulin production. The expected IgG or IgM production in the absence of suppressor effects approximated the sum of IgG or IgM produced by each cell population cultured alone (4 x 106 cells/2 ml) in the presence of optimal amounts of PWM. Percent of expected Ig synthesis by cells in coculture = 100 x (Nanograms of Ig synthesized by 4 x 106 PBL from both subjects in coculture in the presence of PWM/sum of the nanograms of Ig synthesized by 4 x 106 PBL from each subject cultured separately in the presence of PWM). Percent suppression of Ig synthesis = 100 -percent of expected Ig synthesis by cells in co-culture.
Mitomycin C treatment of lymphocytes. Ficoll-Hypaquepurified lymphocytes (5-10 x 106 cells) were incubated with 10 ml of RPMI 1640 containing 50 ,tg/ml of mitomycin C (MMC, Sigma Chemical Co., St. Louis, Mo.) for 30 min at 37°C. After the incubation, the cells were washed three times in PBS.
One-way mixed leukocyte culture. Viable Ficoll-Hypaque-purified but not monocyte-depleted mononuclear cell preparations from normal volunteers (1 x 106 cells/0.1 ml) were incubated with an equal number of MMC-treated allogeneic normal peripheral blood stimulator cells in triplicate cultures in wells of 3008 Multiwell tissuie culture plates. Controls consisted of PBL incubated with autologous MMCtreated PBL. To test if suppressor cells affected the ability of a cell population to stimulate another unrelated cell population in one-way mixed leukocyte culture, viable MMCtreated PBL from multiple myeloma patients or benign monoclonal gammopathy patients were added in varying concentrations (0.5, 1, 2, and 4 x 106 cells /0.1 ml) to the above cultures. Cultures were incubated for 6 days, then they were pulsed for 6 h with [125I]UdR (1 MCi/culture), harvested, and washed. The radioactivity in the harvested cells was determined by counting them in an automatic Searle gamma counter, model 1185 (17) . Results were expressed in counts per minute. The percent suppression in the presence of stimulator cells was calculated as follows: percent expected counts = (cpm of one-way mixed leukocyte culture [MLC] in the presence of a "suppressor" cell population/cpm of one-way MLC in the absence of the suppressor cell population) x 100. Percent suppression = 100 -percent expected counts. If the percent suppression was a negative number, there was no suppression but stimulation instead. Percent suppression of 50% or greater was considered significant inhibition.
Inhibition of MLC by MLC supernates. Supematant fluid was harvested from MLC of allogeneic normals and leukocytes manifesting suppressor activity. 1 (14) CM MYELOMA UNTREATED (5) E3 MYELOMA TREATED (11) .0 8M BENIGN MONOCLONAL (6) 
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RESULTS
Demonstration of antigen-binding cells in the peripheral blood of patients with multiple myelorna. Fig. 1 shows the results of antigen-bindling cell experiments. 14 normal patients tested ranged from 25-69 yr of age. All patients used in the calculations had been immunized against tetanus and diphtheria. PBL from one patient tested who had not been immunized against tetanus or diptheria had less than one antigen-binding cell per 5,000 lymphocytes. This patient's results were not included in the normal group mean. BSA was used in these experiments for baseline purposes. Less than 2 ABC/5000 lymphocytes were present in most patients tested. Of those tested, one untreated patient with multiple myeloma and three patients treated for myeloma had hospital documentation of pneumococcal pneumonia. When means were compared using Student's t test, the number of antigen-binding cells in the peripheral blood of normal patients did not differ at the 95%o confidence level from the number of antigen-binding cells in the peripheral blood of patients treated for myeloma, those with myeloma who were untreated, or those with benign monoclonal gammopathy.
Stimulation of DNA synthesis in pueripherall blood lymphocytes of multiple myeloma patients by nonspecific mitogens or specific antigens. Resullts in Fig.   2A show that the peripheral blood lymphocyte responses to PHA-M or PWM were normal or increased in untreated patients with multiple myeloma but that the PWM response was significantly decreased (P < 0.01) in patients treated for multiple myeloma. (Fig. 3A) or with the nanooma, benign grams of IgM produced in culture by PBL from unatient groups treated and treated IgG multiple myeloma and IgG esis as meas-benign monoclonal gammopathy patients (Fig. 3B) . tion with 25 Fig. 4 . In five untreated multiple myeloma patients tested, the percent suppression of the appropriate immunoglobtulin measured varied from 38-65% in PWM-stimulated cultures, from 31-75% in TT-stimulated cultures, and from 47-82% in PP-stimulated cultures depending on which normal patient was used in the coculture experiment. In 15 treated myeloma patients tested, suppression of the appropriate immunoglobulin synthesis measured varied from 8-61% in PWM-stimulated cultures, from 1-75% in TT-stimulated cultures, and from 1-54% in PP-stimulated cultures. Only 6 out of 15 (Fig. 4) . When the same normal PBL were mixed with PWM and Ficoll-Hypaque-pturified but not monocyte-depleted preparations from the same untreated multiple myeloma patients as above, the observed suppression of immunoglobtulin synthesis was 95, 55, 52, 92, and 75%, respectively. Similarly, when normal PBL were mixed with PWM and monocyte-depleted PBL preparations from treated multiple myeloma patients, 6/15 treated multiple myeloma patients tested suppressed appropriate PWM-stimulated immtunoglobulin synthesis by normal PBL greater than 30% (Fig. 4) . However, when PBL preparations from these treated multiple myeloma patients were used which were not monocyte depleted, 8 present which is independent of a phagocytic Removal of the EA-RFC reduced the observed supmonocyte. pression of in vitro immunoglobulin synthesis more Shown in Fig. 5 are the combined results of five than did the removal of either E-RFL or surface separate experiments using lymphocyte subpopula-immunoglobulin-bearing cells (P < 0.01). In the PWM tion-depletion techniques to determine which cell system, removal of EAC-RFL also reduced the obpopulations had suppressor activity. Experiments served suppression more than did the removal of either were done with monocyte-depleted cell populations. E-RFL or surface immunoglobulin-bearing cells (P Table III . Three untreated multiple myeloma patients and four treated multiple myeloma patients were tested. In the majority of untreated multiple myeloma patients, PWM-stimulated in vitro immunoglobulin production substantially improved when EA-RFC or EAC-RFL subpopulations were removed. However, removal of any of the above cell populations did not improve PWM-stimulated in vitro immunoglobulin production by PBL from treated multiple myeloma patients.
Suppressor cells for other functions. In previous studies (12) , it was shown that PBL from both untreated and treated patients with multiple myeloma had decreased ability to stimulate allogenic normal PBL in a one-way MLC when compared to PBL from normal age-matched patients (P < 0.05). Experiments were performed to determine if this defect could be due to suppressor activity. MMC-treated Ficoll-Hypaquepurified PBL from six different untreated patients with multiple myeloma and from five different patients treated for multiple myeloma were each added to oneway MLC between PBL from 10 different allogeneic normal patients. Four out of six of the untreated myeloma patients MMC-treated PBL preparations suppressed the normal allogeneic one-way MLC response greater than 50% (Table IV) . In three out of six cases, a supernatant factor could be shown to suppress the normal allogeneic response (results not shown). To determine which lymphocyte subpopulation might be involved in the suppressive effect, lymphocyte subpopulation-depleted PBL from multiple myeloma patients were added to one-way MLC between PBL from four allogeneic normal patients. In three out of the four cases, no suppression was observed when EAC-RFL were depleted, and in one case no suppression was observed when E-RFL were depleted (Table V) . No suppressive effects could be demonstrated by PBL from any of the four BMG patients tested, from any of the five treated myeloma patients tested, or from normal PBL tested. It is possible that therapy destroyed the relevant population in the patients who were treated for multiple myeloma. FicollHypaque-purified preparations were used in these experiments. They were not monocyte depleted before (20) . The absence of this latter effect in treated myeloma patients suggests that the cells responsible for this effect are sensitive to alkvlating agents (12) .
Several theories have been proposed to explain the immunological defects in patients with multiple myeloma. First, myeloma cells may release RNA molectules that alter the surface immunoglobulin receptors on B lymphocytes, thus interfering with host recognition of antigen and subsequent antibody formation (21, 22) . Second, a feedback inhibition by chalones may block the expansion of B lymphocytes in response to antigen challenge (3, 4) . Third, immunoregu- In the normal immune response, it appears that suppressor mechanisms, both humoral (24, 25) and cellular (26) , operate simultaneously to maintain a delicate regulatory balance. There is thus the possibility that the immunoproliferative disease in multiple myeloma is a manifestation of an immune defect in a regulatory compartment and a suppressor function defect may be implicated. In other systems, suppressor functions have not only been attributed to T and B cells (16, 27) , but to macropages (28) and nylonadherent nontheta-bearing cells (29) as well.
Unfortunately, demonstration of suppressive effects in vitro does not dignify their importance in the pathogenesis of the disease in which they are found (30) . Suppressor activity has been found after concanavalin A treatment of lymphocytes from normal donors (31 
